Published in Drug Deliv Transl Res on December 01, 2013
Immune cell impact of three differently coated lipid nanocapsules: pluronic, chitosan and polyethylene glycol. Sci Rep (2016) 0.81
Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery. Proc Natl Acad Sci U S A (2016) 0.76
Human Lipocalin-Type Prostaglandin D Synthase-Based Drug Delivery System for Poorly Water-Soluble Anti-Cancer Drug SN-38. PLoS One (2015) 0.75
Vascular Accessibility of Endothelial Targeted Ferritin Nanoparticles. Bioconjug Chem (2016) 0.75
Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy. Front Immunol (2017) 0.75
Ocular Disposition of Ciprofloxacin from Topical, PEGylated Nanostructured Lipid Carriers: Effect of Molecular Weight and Density of Poly (ethylene) glycol. Int J Pharm (2017) 0.75
Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir. Biomaterials (2017) 0.75
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Biodegradable long-circulating polymeric nanospheres. Science (1994) 7.46
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul (2001) 6.59
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev (2010) 5.26
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A (1991) 4.85
Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl (2010) 4.17
Therapeutic synthetic polymers: a game of Russian roulette? Drug Discov Today (2002) 3.96
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res (2003) 3.89
'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces (2000) 3.33
Targeted drug delivery to tumors: myths, reality and possibility. J Control Release (2011) 2.69
Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol (2013) 2.49
PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol (2004) 2.32
Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer (2007) 1.81
In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci (2005) 1.72
Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol (2011) 1.58
Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta (2007) 1.56
Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim Biophys Acta (1991) 1.55
Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. Adv Drug Deliv Rev (1998) 1.55
Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther (2006) 1.51
Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv (2012) 1.46
Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano (2010) 1.41
Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release (2006) 1.36
PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release (2007) 1.34
Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery. FEBS Lett (1997) 1.33
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release (2007) 1.27
Liposome opsonization. J Liposome Res (2005) 1.26
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res (2013) 1.24
Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res (2009) 1.23
Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci (2000) 1.18
Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release (2005) 1.16
Assessment of splenic function. Eur J Clin Microbiol Infect Dis (2010) 1.12
Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J Control Release (2006) 1.09
Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther (2000) 1.08
The role of lipid charge density in the serum stability of cationic lipid/DNA complexes. Biochim Biophys Acta (2004) 1.08
In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: effects on biodistribution and tumor accumulation. J Pharm Sci (2008) 1.08
Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J Control Release (2010) 1.05
Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Biol Lett (2005) 1.03
Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release (2006) 1.02
Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug Chem (2012) 1.02
Cholesterol domains in cationic lipid/DNA complexes improve transfection. Biochim Biophys Acta (2008) 1.00
Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol Immunol (2008) 0.99
T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int J Pharm (2010) 0.99
Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta (2005) 0.97
Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta (2001) 0.96
An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. Life Sci (1995) 0.95
Effect of cholesterol nanodomains on the targeting of lipid-based gene delivery in cultured cells. Mol Pharm (2010) 0.95
Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes. Pharm Res (2012) 0.91
Complement activation and cell uptake responses toward polymer-functionalized protein nanocapsules. Biomacromolecules (2012) 0.89
The effect of cholesterol domains on PEGylated liposomal gene delivery in vitro. Ther Deliv (2011) 0.89
The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J Control Release (2007) 0.87
Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Int J Pharm (2012) 0.86
Anti-polyethyleneglycol antibody response to PEGylated substances. Biol Pharm Bull (2013) 0.86
Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. Biol Pharm Bull (2012) 0.83
Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. Pediatr Blood Cancer (2011) 0.82
Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology (2012) 0.81
Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application. Int J Pharm (2012) 0.80
Connecting drug delivery reality to smart materials design. Int J Pharm (2013) 0.80
Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan. Int J Pharm (2013) 0.78
The effects of lipoplex formulation variables on the protein corona and comparisons with in vitro transfection efficiency. J Control Release (2013) 0.76